Pfizer reported first-quarter 2026 revenue of $14.45 billion, up 5 percent year-over-year and ahead of the $13.79 billion analyst consensus. [1] Adjusted diluted earnings per share came in at $0.75 against a $0.72 expectation. [1] The headline beat is unambiguous. The line buried below the press release is the part the prior week's Apple and Berkshire prints make legible: reported net income fell to $2.687 billion, down 9 percent from $2.967 billion in Q1 2025. Reported diluted EPS came in at $0.47, down 10 percent from $0.52. Adjusted income was $4.29 billion, down 18 percent from $5.237 billion. [2] [3]
The capital-return line is sharper. Pfizer's 8-K filing notes: "No share repurchases have been completed to date in 2026. As of May 5, 2026, Pfizer's remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2026." [4] The company's 2026 EPS guidance — $2.80 to $3.00 adjusted, against $59.5 billion to $62.5 billion in revenue — assumes "approximately 5.74 billion weighted-average shares outstanding, and assumes no share repurchases in 2026." [4] CFO David Denton, on Tuesday's call: "We are reaffirming our full-year 2026 financial guidance." [4]
Tuesday's Pfizer prints into the Covid cliff and a $5 billion year set the print up against the $5 billion-year frame for declining Covid revenue and the broader Big Pharma post-Covid recalibration. Wednesday's frame is the print itself: a top-line beat, a reported net income decline, and zero capital return alongside Apple's $100 billion buyback authorization (May 11 record / May 14 pay) and Berkshire's 14th consecutive net-stock-selling quarter against $397 billion of cash. The capital-return discipline at Pfizer is enforced by the Covid revenue cliff. The capital-return discipline at Apple and Berkshire is voluntary.
The quarter's growth came from the Launched and Acquired Products portfolio — Padcev (the Seagen oncology platform), Eliquis (the Bristol-Myers Squibb-shared blood thinner), Nurtec (the Biohaven migraine acquisition), Vyndaqel cardiovascular, and the Metsera obesity portfolio acquired in late 2025. That category grew 22 percent operationally, against a 2 percent operational increase across the company. [1] [3] Excluding Comirnaty (Covid vaccine) and Paxlovid (Covid antiviral), the underlying business grew 7 percent operationally. [4] The Covid franchise is doing what management has signaled for 18 months: declining at a predictable rate, with the L&A portfolio expected to absorb the loss.
The R&D line is consequential. Adjusted R&D rose approximately 12 percent operationally year-over-year — the largest contributor to the 18 percent adjusted income decline. [3] CFO Denton on the call: "Today, we are reaffirming our full-year 2026 financial guidance." [3] The R&D ramp targets oncology (Padcev expansion, Talzenna combinations, Lorbrena added in Q1) and the obesity pipeline acquired through Metsera. The 20-trial pivotal study count for 2026, which Pfizer has guided across multiple analyst calls, is the multi-year capital allocation Pfizer is making in lieu of buybacks.
What this prints is the disciplined-cohort receipt's mirror image. Apple's $100 billion buyback authorization, which the paper described separately Tuesday, is the disciplined cohort actively rejecting the AI-capex regime in favor of capital return. Pfizer's zero buybacks is capital discipline enforced by patent-cliff math and a Covid franchise unwind; it is not the same posture, even though the line items rhyme. Berkshire's net stock-selling — $24.1 billion sold against $15.9 billion bought in Q1 — is voluntary capital discipline. Pfizer's is structural. The market read the difference Tuesday: PFE rose 0.57 percent in pre-market and held its $148.6 billion market cap. [5]
The 22 percent L&A growth is the part the bull case rests on. CFO Denton's framing — "another set of products that will be excelling us through the end of the decade" — is a multi-year horizon commitment. [1] If the L&A portfolio sustains 22 percent operational growth through 2027 and 2028, the patent-cliff arithmetic clears at the $59.5-$62.5 billion revenue floor. If it doesn't, the no-buyback discipline becomes a multi-year holding pattern rather than a 2026-only choice.
Pfizer's 56-year dividend payment record — the company has maintained or raised the dividend through every quarter since 1970 — is the structural shareholder commitment that the buyback decision sits inside. The dividend yield at $26.06 closing price is approximately 6.54 percent. [5] Dividend continuity is the BigPharma-post-Covid frame's signature; Pfizer is paying out, just not buying back. The capital-allocation choice is a choice about what to defend.
-- THEO KAPLAN, San Francisco